Zhengye Biotechnology Holding (ZYBT) Preferred Stock Liabilities (2024 - 2025)
Zhengye Biotechnology Holding's (ZYBT) quarterly Preferred Stock Liabilities came in at $140.99 in Q4 2025, up 1.28% year-over-year from $139.22 in Q4 2024, and up 1.28% quarter-over-quarter from $139.22 in Q4 2024.
Powered by 
Analysis
Zhengye Biotechnology Holding (ZYBT) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Preferred Stock Liabilities for 2 consecutive years, with $140.99 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Preferred Stock Liabilities rose 1.28% year-over-year to $140.99 in Q4 2025; TTM through Dec 2025 was $140.99, a 1.28% increase from a year earlier, with the FY2025 full-year figure at $140.99, up 1.28% from the prior year.
- Preferred Stock Liabilities was $140.99 for Q4 2025 at Zhengye Biotechnology Holding, up from $139.22 in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $140.99 in Q4 2025 and troughed at $139.22 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.52 Bn | 40.33 Bn | 779.09 Mn | - |
| 2 | Zoetis | 30.69 Bn | 29.02 Bn | 1.05 Bn | - |
| 3 | Elanco Animal Health | 11.89 Bn | 11.36 Bn | 798.00 Mn | - |
| 4 | Phibro Animal Health | 1.50 Bn | 1.42 Bn | 134.40 Mn | - |
| 5 | Immucell | 89.92 Mn | 81.06 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 75.05 Mn | 67.96 Mn | - | 140.99 |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | - |